SCHEMBL7206591

SCHEMBL7206591

COc1ccc2c(c1)/C(=C/CCN1CCC(O)(c3ccc(Br)cc3)CC1)c1cccnc1CO2

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 3/20 0.53
▸ CHRM2 P08172 1/20 0.43
▸ CCR5 P51681 1/20 0.43
▸ DRD2 P14416 3/20 0.41
▸ DRD4 P21917 3/20 0.41
▸ DRD3 P35462 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SLC6A1 P30531 1/20 0.39
▸ SLC6A12 P48065 1/20 0.39
▸ SLC6A11 P48066 1/20 0.39
▸ TBXA2R P21731 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HRH1 P35367 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7206597 1.00 CCR1 (0.53) CCR1CHRM2CCR5DRD2DRD4
SCHEMBL12121529 0.95 CCR1 (0.56) CCR1CHRM2CCR5DRD2DRD4
SCHEMBL14419980 0.93 CCR1 (0.54) CCR1CHRM2CCR5ALDH1A1LMNA
SCHEMBL15478373 0.93 CCR1 (0.54) CCR1CHRM2CCR5ALDH1A1LMNA
SCHEMBL10287667 0.93 CCR1 (0.54) CCR1CHRM2CCR5DRD2DRD3
SCHEMBL7210849 0.92 CCR1 (0.63) CCR1CHRM2CCR5DRD2DRD3
SCHEMBL7210846 0.92 CCR1 (0.63) CCR1CHRM2CCR5DRD2DRD3
SCHEMBL13617244 0.92 CCR1 (0.53) CCR1CHRM2CCR5ALDH1A1LMNA
SCHEMBL14419981 0.90 CCR1 (0.57) CCR1CHRM2CCR5DRD2DRD4
SCHEMBL14419979 0.90 CCR1 (0.52) CCR1CHRM2CCR5ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663537-B2 Chemokine receptor antagonists and methods of use MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-05-30 — — US disclosed
US-6613905-B1 Treating or preventing a disease associated with aberrant leukocyte recruitment and/or activation MILLENNIUM PHARMACEUTICALS, INC. 2003-09-02 — — US disclosed
Send feedback